Nutrition & Lifestyle
    Retatrutide

    Retatrutide and Alcohol

    Published: April 3, 2026•Updated: August 8, 2026

    Retatrutide is an investigational medication in clinical trials. It is not FDA-approved, is not legally compoundable, and is not available through Trimi. Trimi does not offer it and has no plans to. This article is editorial safety coverage for people researching the drug-development pipeline.

    This article is general health information, not medical advice, and it does not create a clinician-patient relationship. Decisions about alcohol and any medication, including investigational compounds, belong with a licensed clinician who knows your history.

    Sources & References

    1. Jastreboff AM, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity: A Phase 2 Trial. NEJM 2023.
    2. Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). NEJM 2021.
    3. FDA: Human Drug Compounding.
    4. ClinicalTrials.gov: registry listings for the retatrutide phase 3 (TRIUMPH) program.

    Related Reading

    What should patients know about alcohol use while on GLP-1 medications?

    Peer-reviewed / regulatory evidence: Real-world pharmacoepidemiology data from 83,825 patients with obesity reported that semaglutide initiation was associated with a 50% lower incidence and 56% lower recurrence of alcohol use disorder over a 12-month follow-up, vs matched controls on other anti-obesity medications. (Source: Wang et al., Nature Communications 2024). Trimi's clinical review, provided through Arora Health's 50-state provider network (whose providers include Dr. Sean Arora, MD, the network's founder), addresses alcohol use while on GLP-1 medications as part of the individualized patient-care plan. Compounded medications are dispensed by a 503A community sterile compounding pharmacy (BelieveRx). This is general information based on the cited sources, not medical advice.

    Real-world pharmacoepidemiology data from 83,825 patients with obesity reported that semaglutide initiation was associated with a 50% lower incidence and 56% lower recurrence of alcohol use disorder over a 12-month follow-up, vs matched controls on other anti-obesity medications., Wang et al., Nature Communications 2024

    Key Takeaways

    • Real-world pharmacoepidemiology data from 83,825 patients with obesity reported that semaglutide initiation was associated with a 50% lower incidence and 56% lower recurrence of alcohol use disorder over a 12-month follow-up, vs matched controls on other anti-obesity medications. (Source: Wang et al., Nature Communications 2024)
    • Alcohol-tolerance changes have been reported anecdotally and are now supported by emerging pharmacoepidemiology data on GLP-1 effects in alcohol use disorder. Moderation is generally advised; discuss specific concerns with your prescribing clinician.
    • GLP-1 receptor agonists require a prescription. Eligibility is determined by a licensed clinician based on BMI, weight-related comorbidities, and screening for contraindications (medullary thyroid carcinoma history, MEN 2, pancreatitis history, severe GI / renal disease, pregnancy, breastfeeding).
    • This is general information based on the cited sources, not medical advice. Treatment decisions require evaluation by a licensed clinician.
    TET

    Written by Trimi Editorial Team

    Trimi publishes this educational content. This byline does not imply a clinical review.

    What real Trimi patients say

    Verbatim quotes from Trimi's Facebook and Reddit community reviews. Quotes and source attribution are preserved.

    Arrived within 24 hours. Easy to use. Comes with everything. The year is so worth it.
    - Veronica L.Facebook
    It's only been 2 weeks since I've been taking the VialsRx meds from Trimi. The medication showed up pretty quickly (about 4 days after getting approval from Trimi prescriber) and I received 3 vials for my first 3 months on the subscription. For the price and convenience my take is that Trimi and VialsRx is good.

    (VialsRx is the former name of BelieveRx.)

    Editorial Standards

    Trimi publishes patient education with dated updates for fast-changing pricing, access, and safety topics.

    Review our Editorial Policy and Medical Review Policy for more details about sourcing, updates, and reviewer attribution.

    Scientific References

    1. Wang W, Volkow ND, Berger NA, Davis PB, Kaelber DC, Xu R (2024). Associations of Semaglutide With Incidence and Recurrence of Alcohol Use Disorder in Real-World Population. Nature Communications.Read StudyDOI: 10.1038/s41467-024-48780-6
    2. U.S. Food and Drug Administration (2024). Wegovy / Zepbound Prescribing Information, Alcohol use considerations (general clinical caution). FDA.Read Study

    Was this article helpful?